AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 201 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,664,610 | -22.1% | 107,661 | -10.9% | 0.00% | 0.0% |
| Q2 2023 | $3,420,064 | +45.4% | 120,765 | +17.9% | 0.00% | +50.0% |
| Q1 2023 | $2,352,840 | -13.2% | 102,431 | +6.1% | 0.00% | -33.3% |
| Q4 2022 | $2,710,282 | +8.7% | 96,520 | +9.5% | 0.00% | 0.0% |
| Q3 2022 | $2,494,000 | +49.4% | 88,176 | +17.1% | 0.00% | +50.0% |
| Q2 2022 | $1,669,000 | -30.7% | 75,275 | -9.1% | 0.00% | 0.0% |
| Q1 2022 | $2,409,000 | -12.4% | 82,803 | -1.0% | 0.00% | +100.0% |
| Q4 2021 | $2,750,000 | -29.3% | 83,663 | -0.7% | 0.00% | -50.0% |
| Q3 2021 | $3,889,000 | -15.8% | 84,259 | +0.5% | 0.00% | 0.0% |
| Q2 2021 | $4,619,000 | -17.9% | 83,833 | -23.0% | 0.00% | -33.3% |
| Q1 2021 | $5,625,000 | -9.1% | 108,938 | -23.7% | 0.00% | 0.0% |
| Q4 2020 | $6,189,000 | +45.8% | 142,851 | +17.8% | 0.00% | 0.0% |
| Q3 2020 | $4,245,000 | -27.9% | 121,313 | +10.1% | 0.00% | -25.0% |
| Q2 2020 | $5,890,000 | +87.2% | 110,140 | +24.2% | 0.00% | +33.3% |
| Q1 2020 | $3,146,000 | -36.8% | 88,677 | -14.9% | 0.00% | -25.0% |
| Q4 2019 | $4,976,000 | +315.0% | 104,198 | +181.7% | 0.00% | +300.0% |
| Q3 2019 | $1,199,000 | -49.7% | 36,983 | -22.7% | 0.00% | -50.0% |
| Q2 2019 | $2,386,000 | -4.8% | 47,844 | +28.7% | 0.00% | 0.0% |
| Q1 2019 | $2,507,000 | +27.0% | 37,171 | -13.2% | 0.00% | 0.0% |
| Q4 2018 | $1,974,000 | -23.6% | 42,835 | +27.9% | 0.00% | 0.0% |
| Q3 2018 | $2,583,000 | -13.5% | 33,490 | -5.5% | 0.00% | -33.3% |
| Q2 2018 | $2,986,000 | -18.3% | 35,446 | -20.7% | 0.00% | 0.0% |
| Q1 2018 | $3,653,000 | +88.1% | 44,671 | +31.5% | 0.00% | +50.0% |
| Q4 2017 | $1,942,000 | -67.4% | 33,978 | -61.9% | 0.00% | -66.7% |
| Q3 2017 | $5,952,000 | -18.4% | 89,167 | -37.1% | 0.01% | -14.3% |
| Q2 2017 | $7,291,000 | -27.6% | 141,730 | -17.8% | 0.01% | -22.2% |
| Q1 2017 | $10,072,000 | +88.4% | 172,465 | +34.6% | 0.01% | +80.0% |
| Q4 2016 | $5,347,000 | -17.3% | 128,133 | +4.7% | 0.01% | -16.7% |
| Q3 2016 | $6,462,000 | +54.4% | 122,349 | +22.5% | 0.01% | +20.0% |
| Q2 2016 | $4,184,000 | -22.9% | 99,887 | -25.3% | 0.01% | -28.6% |
| Q1 2016 | $5,430,000 | +59.6% | 133,741 | +155.1% | 0.01% | +75.0% |
| Q4 2015 | $3,403,000 | -6.3% | 52,428 | +1.9% | 0.00% | 0.0% |
| Q3 2015 | $3,631,000 | -62.9% | 51,450 | -41.6% | 0.00% | -60.0% |
| Q2 2015 | $9,791,000 | +93.7% | 88,093 | +64.4% | 0.01% | +100.0% |
| Q1 2015 | $5,055,000 | +13.0% | 53,599 | +34.2% | 0.01% | +25.0% |
| Q4 2014 | $4,474,000 | +36.7% | 39,947 | -25.1% | 0.00% | +33.3% |
| Q3 2014 | $3,273,000 | +412.2% | 53,354 | +282.9% | 0.00% | +200.0% |
| Q2 2014 | $639,000 | -27.7% | 13,935 | -38.3% | 0.00% | 0.0% |
| Q1 2014 | $884,000 | +231.1% | 22,587 | +102.4% | 0.00% | – |
| Q4 2013 | $267,000 | -23.5% | 11,157 | -10.5% | 0.00% | – |
| Q3 2013 | $349,000 | – | 12,470 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |